Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CTSH | P09668 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945995 | 0.88 | CTSK (0.34) | CTSKCTSLCTSBCYP1A2CYP3A4 | |
| SCHEMBL2952272 | 0.88 | CTSK (0.34) | CTSKCTSLCTSBCYP1A2CYP3A4 | |
| SCHEMBL2948636 | 0.87 | CTSK (0.33) | CTSKCTSLCTSBCYP1A2CYP3A4 | |
| SCHEMBL2946413 | 0.86 | CTSK (0.37) | CTSKCTSLCTSBCYP1A2CYP3A4 | |
| SCHEMBL2953188 | 0.85 | CYP1A2 (0.33) | CTSKCTSLCTSBCYP1A2CYP3A4 | |
| SCHEMBL2954390 | 0.81 | CTSK (0.37) | CTSKCTSLCTSBCYP1A2CYP3A4 | |
| SCHEMBL2957079 | 0.79 | CTSK (0.37) | CTSKCTSLCTSBCYP1A2CYP3A4 | |
| SCHEMBL2947848 | 0.78 | GABBR2 (0.36) | CTSK | |
| SCHEMBL2948784 | 0.77 | METAP2 (0.32) | CTSKCTSLCTSBCYP1A2CYP3A4 | |
| SCHEMBL2949220 | 0.77 | METAP1 (0.33) | CYP1A2CYP3A4METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585996-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-08 | — | — | US | claimed |
| US-7749985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7585996-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286759-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, NAPEPLD, AASDHPPT | CTSK 1342/4885CTSL 336/4885CTSB 841/4885 |
| US-20080146526-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, NAPEPLD, AASDHPPT | CTSK 1342/4885CTSL 336/4885CTSB 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.